CK-2017357 clinical trials
Also written tirasemtiv and CK-2017357.
How each study uses CK-2017357 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2010 (3)
| Year | Studies |
|---|---|
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses CK-2017357 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study for Patients Who Completed VITALITY-ALS (CY 4031)CompletedPhase 3CytokineticsNCT02936635Written as tirasemtivHow we know
- Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a YearCompletedPhase 3CytokineticsNCT02496767Written as TirasemtivHow we know
- Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2CytokineticsNCT01709149Written as CK-2017357How we know
- Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia GravisTerminatedPhase 2CytokineticsNCT01268280Written as 250 mg CK-2017357How we know
- A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic ClaudicationCompletedPhase 2CytokineticsNCT01131013Written as 375 mg CK-2017357How we know
- A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2CytokineticsNCT01089010Written as 250 mg CK-2017357How we know
- A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2CytokineticsNCT01378676Written as CK-2017357 (Part A)How we know
- Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 2CytokineticsNCT01486849Written as CK-2017357How we know